OncoMatch/Clinical Trials/NCT05797467
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
Is NCT05797467 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including FOLFOX chemotherapy regimens and Bevacizumab for colorectal cancer.
Treatment: FOLFOX chemotherapy regimens · Bevacizumab — The goal of this clinical trial\] is to compare in resectable stage T3-4N2 colorectal cancer. The main question it aims to answer is: whether the use of targeted therapy in combination with adjuvant chemotherapy is associated with improved disease-free survival (DFS) compared to adjuvant chemotherapy alone.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage PT3, PT4
pT3-4N2 stage colorectal adenocarcinoma after surgery
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
No coagulation dysfunction
Kidney function
No severe kidney dysfunction
Liver function
No severe liver dysfunction
Cardiac function
No severe cardio-pulmonary dysfunction
Patients with severe liver, kidney, cardio-pulmonary, coagulation dysfunction, or underlying diseases that cannot tolerate chemotherapy [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05797467 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage PT3 or PT4 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages